Pioneering Galectin-3 Therapeutics through Human Data & Artificial Intelligence

Clinical proof powering next-generation intelligence.

Most AI drug companies began with code and no human data. TrueBinding began with the opposite: TB006, a therapeutic antibody already shown to engage Galectin-3 in people—raising plasma levels ~9x in Alzheimer’s and Parkinson’s. The Galectin Intelligence Platform turns that clinical readout into predictive AI.

The Galectin Intelligence Platform

A Self-Reinforcing Clinical & AI Flywheel

Every clinical readout sharpens our predictive models, refines trial design, and uncovers next-generation targets.

STEP 01

Drug

→
STEP 02

Human data

↑
Each trial makes the next one smarter.
↓
STEP 04

Better trials and new targets

←
STEP 03

AI

Computational Biology & AI

Translating Human Data into Clinical Precision

Integrating predictive modeling and human pathway insights across every stage of Galectin-3 therapeutic development.

Prognostic digital twins

For each trial participant, the platform models the course their disease would most likely have taken without treatment. That makes the trial more sensitive to real drug effects, so future trials can be smaller and read out with more confidence. This is the same class of prognostic method regulators have qualified for trial design.

Responder enrichment

Not every patient benefits equally. The platform learns, from human data, which patients respond — so the next trial enrolls the people the drug actually helps, instead of diluting the signal.

Target discovery

Galectin-3 perturbation in people is a direct readout of what the pathway does in human biology. The platform mines that data for the next generation of Galectin-3 antibodies and for new targets the pathway reveals.

If it works in the brain, it works everywhere.

Neurodegeneration is the "ultimate test" for any healthspan platform. The blood-brain barrier and microglial complexity represent the most difficult environments to resolve chronic inflammation.

Demonstrating Gal-3 inhibition in this highly restrictive environment effectively de-risks the broader potency of our systemic antibody.

TB006 Expanded Access Program

The FDA-authorized Expanded Access Program (EAP) for investigational TB006 permits eligible patients with dementia, including Alzheimer’s disease to request access to the product outside of clinical trials. The program is intended for patients with serious or life-threatening conditions who are unable to participate in clinical studies and who lack satisfactory alternative treatment options.

TB006 is an investigational drug, and its safety and effectiveness have not been established. The Expanded Access Program operates in accordance with FDA regulations while clinical development of TB006 continues.

Completion of Phase 1b/2a Clinical Trial for Alzheimer's Disease

Topline data from a one-month TB006 treatment regimen shows improvements in Clinical Dementia Rating-Sum of Boxes (CDR-SB) in patients, indicating the potential of slowing or reducing clinical decline. Key secondary endpoints were consistent with the primary findings.

Latest News

April, 2026

The FDA has renewed the Expanded Access Program (NCT05959239) for TB006 in treating dementia and Alzheimer's disease. This renewal allows existing patients to continue receiving TB006 outside of traditional clinical trials and offers hope for patients seeking alternative treatment options.

November, 2025

In a recent abstract published in Neuro-Oncology, TrueBinding partnered with UCSF to present new findings under a supplement of the journal’s 2025 volume.

Vo A. H., Yang E., Raleigh D. R., Lan N., Savic R., Butowski N. “TIP-02. Evaluation of TB006, a Galectin-3 antibody, for the treatment of Glioblastoma.” Neuro-Oncology, vol. 27, supplement 5, Nov. 2025, p. v420.

April 13, 2026

TrueBinding has completed the enrollment for Phase 2a Parkinson’s trial (NCT06773962) .This trial will be evaluating the safety and efficacy of this treatment in patients with early to mild Parkinson’s Disease.